Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,211 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00818441 | Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung | completed | Phase 2 | 119 | PfizerINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT01241591 | A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis | completed | Phase 3 | 1,101 | PfizerINDUSTRY | 26 | Dec 26, 2018 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT03130140 | MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions | completed | N/A | 244 | Chinese University of Hong KongOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03295591 | Circulating Tumor Cells in mCRC for Liver Resection | unknown | — | 77 | The University of Hong KongOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT01933945 | Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib(OPTIMIS) | completed | — | 1,676 | BayerINDUSTRY | 31 | Nov 6, 2018 | clinicaltrials |
| NCT02648425 | Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | completed | Phase 1 | 31 | ASLAN PharmaceuticalsOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT03276715 | Prognostic Factors on Malignant Pleural Effusion | completed | — | 233 | The University of Hong KongOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT03331172 | HIFU Reapplication in Benign Nodules | completed | N/A | 28 | The University of Hong KongOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 99 | Puma Biotechnology, Inc.INDUSTRY | 6 | Sep 26, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01923168 | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | completed | Phase 2 | 340 | Novartis PharmaceuticalsINDUSTRY | 17 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | completed | Phase 3 | 452 | Hoffmann-La RocheINDUSTRY | 23 | Aug 14, 2018 | clinicaltrials |
| NCT03623087 | SIMPLE Chemotherapy for NK Lymphoma/Leukaemia | unknown | Phase 3 | 68 | The University of Hong KongOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03625583 | The Hong Kong CML Registry | unknown | — | 200 | The University of Hong KongOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT02795390 | Clinical Trial on Palliative Cancer Patients With Constipation | completed | Phase 2 | 60 | Hong Kong Baptist UniversityOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT02815436 | Effectiveness of Tel and SMS Reminder on Compliance With CRC Screening | completed | N/A | 600 | Chinese University of Hong KongOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03197116 | Lay Tel Compliance Study | completed | N/A | 500 | Chinese University of Hong KongOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02521727 | To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas(NonAA) | completed | — | 828 | Chinese University of Hong KongOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02977845 | Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety. | completed | N/A | 162 | Nam Dinh University of NursingOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT01352728 | Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib | completed | Phase 2 | 50 | Chinese University of Hong KongOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT01248897 | Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib(BioPATH) | completed | — | 158 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT01462604 | Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer | completed | — | 27 | GlaxoSmithKlineINDUSTRY | 4 | Jun 19, 2018 | clinicaltrials |
| NCT03071822 | Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas | unknown | Phase 4 | 50 | The University of Hong KongOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT03131986 | Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia | unknown | — | 30 | The University of Hong KongOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT03143036 | Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma | unknown | Phase 2 | 100 | National University Hospital, SingaporeOTHER | 4 | Jun 7, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT02398721 | Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules | completed | N/A | 314 | The University of Hong KongOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT02991638 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | unknown | Phase 3 | 62 | The University of Hong KongOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT02702050 | Effect of Mechanical Stimulation on Mastectomy Scars | completed | N/A | 108 | The Queen Elizabeth HospitalOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT03482570 | Activity Behaviours in Patients With Malignant Pleural Effusion | unknown | — | 200 | The University of Hong KongOTHER | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01024036 | A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease | completed | Phase 2 | 79 | Janssen Research & Development, LLCINDUSTRY | 23 | Mar 21, 2018 | clinicaltrials |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | completed | Phase 3 | 2,098 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 19, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | terminated | N/A | 42 | Chinese University of Hong KongOTHER | 1 | Jan 26, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials